BioWorld A closer look BioWorld Asia BioWorld Science

BioWorld

Walking the talk, Kyverna phase II stiffens miv-cel CAR T case
Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a positive primary analysis from its registrational...

More in BioWorld

BioWorld Science

AI opens the way to systematic risk assessment of zoonotic potential of viruses
Researchers in the U.K. have developed an AI-driven method of identifying viruses in wild animals with the potential to spillover into humans. The technique makes it...

More in BioWorld Science

A closer look

Med-tech financings steady at $8.8B in Q1, despite volume drop
Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent...

More in A closer look

BioWorld Asia

Biogen amasses full felzartamab rights with $850M TJ deal
Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year...

More in BioWorld Asia

BioWorld Insider podcast

The opioid crisis may not be front and center anymore, but it’s raging still. Elysium Therapeutics Inc. CEO Greg Sturmer talks about his firm’s candidate for a solution to the medical and societal problem.